However, combining CXCR4 or CCR5 antagonists with anti-PD1 immunotherapy has shown promising results in clinical studies in patients with colorectal cancer and pancreatic ductal adenocarcinoma [63,64]. The gene discussed is CCR5; the disease is colorectal cancer.